OBR Daily Commentary

forumImage

Hospitals Sue HHS to Stop Cuts to Medicare Drug Payment Program

(Bloomberg) Nov 13, 2017 - Hospitals and several of their trade organizations sued the U.S. Department of Health and Human Services to stop cuts to a Medicare program that lets facilities that serve low-income patients buy drugs at a discount and then get reimbursed at a higher rate.

Read Article arrow

Ted Okon (Posted: November 14, 2017)

quotesThis injunction filed by 3 hospital organizations and 3 hospitals will be interesting to watch. Regardless, 340B hospitals are clearly in the crosshairs of this Administration and Congress. On the other side, the hospitals are fighting mad to retain all the 340B profits available to them. As I have said many times during the past few years, 340B is a financial bubble that has to pop. It is simply not sustainable.quotes

Add Comment 1 Comment
forumImage

Cancer Drug Prices Are So High That Doctors Will Test Cutting Doses

(Washington Post/To Your Health) June 8, 2017 - A group of prominent cancer doctors is planning a novel assault on high drug costs, using clinical trials to show that many oncology medications could be taken at lower doses or for shorter periods without hurting their effectiveness.

Read Article arrow

Ted Okon (Posted: June 09, 2017)

quotesThis seems to be band-aiding the drug price issue, which near the root are the increasing discounts (340B) and rebates (PBMs) that are fueling increasing drug prices. So, where does this approach lead and end? Constantly cutting drug dosages to find the bare minimum needed?quotes

Add Comment 1 Comment
forumImage

Sanofi Pegs U.S. Drug Price Rises to Below Healthcare Inflation

(Reuters) May 9, 2017 - French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

Read Article arrow

Ted Okon (Posted: May 10, 2017)

quotesAnother company making the right move to control drug prices, especially in cancer. In community oncology we are advancing "value-based" payments for services. The same thing needs to be done for drugs. It's time for those really wanting to advance the quality and affordability of cancer care to step up and innovate.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...